Stay updated with breaking news from Disability Outcomes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY® injection Presentation highlights include data for...
Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 (olanzapine) and AJOVY® (fremanezumab) injectionPresentation highlights include data for AUSTEDO in the tardive dyskinesia (TD) START study on real-world effectiveness and adherence when...
16 presentations will examine safety and efficacy of AJOVY and AUSTEDOTEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the company’s neurology portfolio treatments, AJOVY® (fr...